Charcterization of COVID-19 hospitalized adult patients, vaccinated vs non-vaccinated in Duhok province
DOI:
https://doi.org/10.22317/jcms.v8i6.1272Keywords:
COVID-19, Vaccinated, unvaccinatedAbstract
Objectives: First, to determine prevalence of vaccinated COVID-19 patients among hospitalized patients; Second, to determine the epidemiological, clinical, and laboratory characteristics of vaccinated and unvaccinated COVID-19 patients.
Methods: The study was carried out on 300 adult COVID-19 hospitalized patients at Duhok COVID-19 health facilities. A prospective cross-sectional study was used as the study design. Between October 1, 2021, and March 31, 2022, all patients with PCR-confirmed COVID-19 were enrolled.
Results: The majority of people in this study were unvaccinated. Pfizer was most popular among people who had received vaccination. The majority of hospitalized patients were old ages, the mean age was 60.73 ± 15.83 yr. In our study, the unvaccinated females had higher infection rates while vaccinated males had higher hospital admission rates. In our study, vaccinated patients had shorter hospital duration stays. In both vaccinated and unvaccinated patients, predominated cases were severe cases. D dimer was significantly higher among vaccinated patients. The mortality rate was relatively high among both groups. Patients who had received vaccinations tended to experience vomiting and flu-like symptoms more frequently than those who had not. In terms of comorbidities, smoking and malignancy were significant risk factors for COVID-19 infection in unvaccinated patients.
Conclusion: We looked at 300 COVID-19 hospitalized patients. In this study, the majority of people were unvaccinated. Pfizer, had higher prevalence among vaccinated individuals. Majority were elderly. The unvaccinated cases had a higher rate of female hospital admissions than male. The D.Dimer level was significantly different between the two groups. Vomiting and flu-like illness showed higher prevalence in vaccinated cases with significant difference. Smoking and malignancy were significant risk factors for COVID-19 infection in unvaccinated patients. In the fight against a public health disaster like a COVID-19 pandemic, the availability of a COVID-19 vaccines campaign are crucial.
References
García-Basteiro AL, Chaccour C, Guinovart C, Llupià A, Brew J, Trilla A, et al. Monitoring the COVID-19 epidemic in the context of widespread local transmission. The Lancet Respiratory medicine. 2020;8(5):440-2. doi: 10.1016/s2213-2600(20)30162-4.
https://pubmed.ncbi.nlm.nih.gov/32247325/
Lotfi M, Hamblin MR, Rezaei N. COVID-19: Transmission, prevention, and potential therapeutic opportunities. Clinica chimica acta; international journal of clinical chemistry. 2020;508:254-66. doi: 10.1016/j.cca.2020.05.044.
https://pubmed.ncbi.nlm.nih.gov/32474009/
Vetter P, Vu DL, L’Huillier AG, Schibler M, Kaiser L, Jacquerioz F. Clinical features of covid-19. British Medical Journal Publishing Group; 2020
Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. The lancet. 2020;395(10223):507-13.
Ahn D-G, Shin H-J, Kim M-H, Lee S, Kim H-S, Myoung J, et al. Current status of epidemiology, diagnosis, therapeutics, and vaccines for novel coronavirus disease 2019 (COVID-19). 2020.
Pourbagheri-Sigaroodi A, Bashash D, Fateh F, Abolghasemi H. Laboratory findings in COVID-19 diagnosis and prognosis. Clinica Chimica Acta. 2020;510:475-82.
Abdulkader M, Merza M. The evaluation of COVID-19 vaccination program in Duhok province, Iraqi Kurdistan: challenges and solutions. Journal of Research and Health. 2022;12(4):2-2.
Food and Drug Administration (FDA). Emergency Use Authorization, List of COVID-19 Vaccines Authorized by the FDA [Available from:
https://www.fda.gov.ph/list-of-fda-issued-emergency-use-authorization/.
Almufty HB, Mohammed SA, Abdullah AM, Merza MA. Potential adverse effects of COVID19 vaccines among Iraqi population; a comparison between the three available vaccines in Iraq; a retrospective cross-sectional study. Diabetes & metabolic syndrome. 2021;15(5):102207. doi: 10.1016/j.dsx.2021.102207.
https://pubmed.ncbi.nlm.nih.gov/34280733/
Tenforde MW, Patel MM, Ginde AA, Douin DJ, Talbot HK, Casey JD, et al. Effectiveness of SARS-CoV-2 mRNA vaccines for preventing Covid-19 hospitalizations in the United States. MedRxiv. 2021.
Almufty HB, Mamani MMA, Ali AH, Merza MA. COVID‐19 vaccine breakthrough infection among fully vaccinated healthcare workers in Duhok governorate, Iraqi Kurdistan: A retrospective cohort study. Journal of Medical Virology. 2022.
NIH. Clinical Spectrum of SARS-CoV-2 Infection. National Institute of Health. 2022.
https://www.covid19treatmentguidelines.nih.gov/overview/clinical-spectrum/
Moline HL, Whitaker M, Deng L, Rhodes JC, Milucky J, Pham H, et al. Effectiveness of COVID-19 vaccines in preventing hospitalization among adults aged≥ 65 years—COVID-NET, 13 states, February–April 2021. Morbidity and Mortality Weekly Report. 2021;70(32):1088.
Binesh M, Pahlevanian A, Rahimi S, Ahmadizadeh Z. Relationship Between COVID-19-related Factors and Self-management Behaviors in People with Type-2 Diabetes: A Cross-sectional Study. Middle East Journal of Rehabilitation and Health Studies. 2022;9(3).
Karagun B, Evran M, Odabas F, Akkus G, Kurtaran B, Sert M, et al. Awareness of Vaccination against Respiratory Tract Diseases, Including Pneumonia, Influenza, and COVID-19 in Patients with Diabetes Mellitus. International Journal of Clinical Practice. 2022;2022.
Tourkmani AM, Bin Rsheed AM, AlEissa MS, Alqahtani SM, AlOtaibi AF, Almujil MS, et al. Prevalence of COVID-19 Infection among Patients with Diabetes and Their Vaccination Coverage Status in Saudi Arabia: A Cross-Sectional Analysis from a Hospital-Based Diabetes Registry. Vaccines. 2022;10(2):310.
Nachimuthu S, Viswanathan V. Trend in COVID-19 vaccination among people with diabetes: A short study from India. Diabetes & metabolic syndrome. 2021;15(4):102190.
Valladares-Garrido MJ, Zeña-Ñañez S, Peralta CI, Puicón-Suárez JB, Díaz-Vélez C, Failoc-Rojas VE. COVID-19 Vaccine Effectiveness at a Referral Hospital in Northern Peru: A Retrospective Cohort Study. Vaccines. 2022;10(5):812.
Abdulkader M, Merza MJJoR, Health. The evaluation of COVID-19 vaccination program in Duhok province, Iraqi Kurdistan: challenges and solutions. Journal of Research & Health. 2022;12(4):2-.
http://jrh.gmu.ac.ir/browse.php?a_id=2070&sid=1&slc_lang=en&ftxt=0
Al Houri HN, Al-Tarcheh H, Zahra E, Al-Tarcheh A, Armashi H, Alhalabi M. Clinical Characteristics and Prognosis of COVID-19 patients in Syria: A cross-sectional multicenter study. Annals of medicine and surgery (2012). 2022;78:103816. doi: 10.1016/j.amsu.2022.103816.
https://pubmed.ncbi.nlm.nih.gov/35620045/
Ambrosino I, Barbagelata E, Ortona E, Ruggieri A, Massiah G, Giannico OV, et al. Gender differences in patients with COVID-19: a narrative review. Monaldi Archives for Chest Disease. 2020;90(2).
Lakbar I, Luque-Paz D, Mege JL, Einav S, Leone M. COVID-19 gender susceptibility and outcomes: A systematic review. PloS one. 2020;15(11):e0241827. doi: 10.1371/journal.pone.0241827.
https://pubmed.ncbi.nlm.nih.gov/33141872/
Aldamen T, Asad M, Yaqoub M, Alhawaratt M, Aqel A, Asad MM. Effectiveness of Vaccination: Hospital Admission and Length of Stay. Iproceedings. 2022;8(1):e36363.
Merza MA, Aswad SM, Sulaiman HM, Abdulah DM, Rasheed WS, Taib NI. Clinical and epidemiological characteristics and outcomes of Coronavirus disease-19 patients in a large longitudinal study. International journal of health sciences. 2021;15(4):29.
Christie A, Henley SJ, Mattocks L, Fernando R, Lansky A, Ahmad FB, et al. Decreases in COVID-19 cases, emergency department visits, hospital admissions, and deaths among older adults following the introduction of COVID-19 vaccine—United States, September 6, 2020–May 1, 2021. Morbidity and Mortality Weekly Report. 2021;70(23):858.
Uaprasert N, Watanaboonyongcharoen P, Vichitratchaneekorn R, Trithiphen S, Akkawat B, Sukperm A, et al. Prevalence of thrombocytopenia, anti-platelet factor 4 antibodies and D-dimer elevation in Thai people After ChAdOx1 nCoV-19 vaccination. Research and practice in thrombosis and haemostasis. 2021;5(6):e12580. doi: 10.1002/rth2.12580.
https://pubmed.ncbi.nlm.nih.gov/34568726/
Guner G, Yurumez Y, Durmus E, Guneysu F, Aslan N. Observation of COVID-19 Vaccinated and Unvaccinated Patients. RESEARCH AND CLINICAL MEDICINE JOURNAL. 2020(4).
https://www.resclinmed.eu/public/data_files/articles/146/article_146.pdf
Almufty HB, Mohammed SA, Abdullah AM, Merza MA. Potential adverse effects of COVID19 vaccines among Iraqi population; a comparison between the three available vaccines in Iraq; a retrospective cross-sectional study. Diabetes & Metabolic Syndrome: Clinical Research & Reviews. 2021;15(5):102207.
Havers FP, Pham H, Taylor CA, Whitaker M, Patel K, Anglin O, et al. COVID-19-associated hospitalizations among vaccinated and unvaccinated adults≥ 18 years–COVID-NET, 13 states, January 1–July 24, 2021. MedRxiv. 2021.
Barry M, AlMohaya A, AlHijji A, Akkielah L, AlRajhi A, Almajid F, et al. Clinical characteristics and outcome of hospitalized COVID-19 patients in a MERS-CoV endemic area. Journal of Epidemiology and Global Health. 2020;10(3):214.
Scott J, Anderson J, Mallak N, Beitinjaneh B, Wei K, Otaki F. Gastroparesis After Pfizer-BioNTech COVID-19 Vaccination. The American journal of gastroenterology. 2021;116(11):2300. doi: 10.14309/ajg.0000000000001354.
https://pubmed.ncbi.nlm.nih.gov/34187985/
van Zyl-Smit RN, Richards G, Leone FT. Tobacco smoking and COVID-19 infection. The Lancet Respiratory medicine. 2020;8(7):664-5. doi: 10.1016/s2213-2600(20)30239-3.
https://pubmed.ncbi.nlm.nih.gov/32464099/
Rashedi J, Mahdavi Poor B, Asgharzadeh V, Pourostadi M, Samadi Kafil H, Vegari A, et al. Risk Factors for COVID-19. Le infezioni in medicina. 2020;28(4):469-74.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Journal of Contemporary Medical Sciences
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
